External validation suggests integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas

BMC Cancer

Volumn 9, Issue , 2009, Pages 336-

  Partheen, Karolina ^a   Levan, Kristina ^a   Österberg, Lovisa ^a   Claesson, Ingela ^a   Sundfeldt, Karin ^a   Horvath, György ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN CAPPING PROTEIN; BETA3 INTEGRIN; BIOLOGICAL MARKER; CLUSTERIN; PROTEIN PRAME; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVOR; EXTERNAL VALIDITY; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN BETA3; MICROFILAMENT PROTEINS; MIDDLE AGED; NEOPLASM STAGING; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70449441112     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-336     Document Type: Article

References (35)

1. Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001, 127(2):73-79. 10.1007/s004320000153, 11216917.
2. Socialstyrelsen TSNBoHaW Statistics - Health and Diseases 2007:15. Causes of death, Sweden 2005. 2007, The Swedish National Board of Health and Welfare; Sweden.
3. Fox H. Pathology of ovarian Cancer. Cancer in Women 1998, 415-442. Oxford: Blackwell Science, Inc, Kavanagh JJ, Singletary SE, Einhorn N, DePetrillo AD.
4. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HY, Pecorelli S, Beller U. Carcinoma of the ovary. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S161-192. 10.1016/S0020-7292(06)60033-7, 17161157.
5. Partheen K, Levan K, Osterberg L, Horvath G. Expression analysis of stage III serous ovarian adenocarcinoma distinguishes a sub-group of survivors. Eur J Cancer 2006, 42(16):2846-2854. 10.1016/j.ejca.2006.06.026, 16996261.
6. Gyorffy B, Dietel M, Fekete T, Lage H. A snapshot of microarray-generated gene expression signatures associated with ovarian carcinoma. Int J Gynecol Cancer 2008, 18(6):1215-1233. 10.1111/j.1525-1438.2007.01169.x, 18217975.
7. Partheen K, Levan K, Osterberg L, Claesson I, Fallenius G, Sundfeldt K, Horvath G. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 2008, 123(9):2130-2137. 10.1002/ijc.23758, 18709641.
8. Nachman RL, Leung LL. Complex formation of platelet membrane glycoproteins IIb and IIIa with fibrinogen. J Clin Invest 1982, 69(2):263-269. 10.1172/JCI110448, 370974, 6460044.
9. Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001, 305(3):285-298. 10.1007/s004410100417, 11572082.
10. Tamkun JW, DeSimone DW, Fonda D, Patel RS, Buck C, Horwitz AF, Hynes RO. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 1986, 46(2):271-282. 10.1016/0092-8674(86)90744-0, 3487386.
11. Michel D, Chatelain G, North S, Brun G. Stress-induced transcription of the clusterin/apoJ gene. Biochem J 1997, 328(Pt 1):45-50. 1218885, 9359832.
12. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999, 274(11):6875-6881. 10.1074/jbc.274.11.6875, 10066740.
13. Yang CR, Leskov K, Hosley-Eberlein K, Criswell T, Pink JJ, Kinsella TJ, Boothman DA. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death. Proc Natl Acad Sci USA 2000, 97(11):5907-5912. 10.1073/pnas.97.11.5907, 18532, 10823943.
14. Yin HL. Gelsolin: calcium- and polyphosphoinositide-regulated actin-modulating protein. Bioessays 1987, 7(4):176-179. 10.1002/bies.950070409, 2825660.
15. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004, 61(19-20):2614-2623. 10.1007/s00018-004-4225-6, 15526166.
16. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005, 122(6):835-847. 10.1016/j.cell.2005.07.003, 16179254.
17. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3(7):RESEARCH0034. 10.1186/gb-2002-3-7-research0034, 126239, 12184808.
18. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. Modulation of different clusterin isoforms in human colon tumorigenesis. Oncogene 2004, 23(13):2298-2304. 10.1038/sj.onc.1207404, 14755245.
19. Jhala N, Jhala D, Vickers SM, Eltoum I, Batra SK, Manne U, Eloubeidi M, Jones JJ, Grizzle WE. Biomarkers in Diagnosis of pancreatic carcinoma in fine-needle aspirates. Am J Clin Pathol 2006, 126(4):572-579. 10.1309/CEV30BE088CBDQD9, 17019794.
20. Gilks CB, Vanderhyden BC, Zhu S, Rijn M, Longacre TA. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005, 96(3):684-694. 10.1016/j.ygyno.2004.11.039, 15721412.
21. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A, Corti A. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000, 60(1):28-34.
22. Van Ginkel PR, Gee RL, Walker TM, Hu DN, Heizmann CW, Polans AS. The identification and differential expression of calcium-binding proteins associated with ocular melanoma. Biochim Biophys Acta 1998, 1448(2):290-297. 10.1016/S0167-4889(98)00133-5, 9920419.
23. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997, 6(2):199-208. 10.1016/S1074-7613(00)80426-4, 9047241.
24. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004, 10(13):4307-4313. 10.1158/1078-0432.CCR-03-0813, 15240516.
25. Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007, 56(1):95-106. 10.1136/gut.2005.083691, 16847067.
26. Thiagarajan P, Shapiro SS, Levine E, DeMarco L, Yalcin A. A monoclonal antibody to human platelet glycoprotein IIIa detects a related protein in cultured human endothelial cells. J Clin Invest 1985, 75(3):896-901. 10.1172/JCI111789, 423621, 3156882.
27. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(16):9482-9487. 10.1073/pnas.1633689100, 170944, 12874388.
28. Felding-Habermann B, Fransvea E, O'Toole TE, Manzuk L, Faha B, Hensler M. Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells. Clin Exp Metastasis 2002, 19(5):427-436. 10.1023/A:1016377114119, 12198771.
29. Liapis H, Adler LM, Wick MR, Rader JS. Expression of alpha(v)beta3 integrin is less frequent in ovarian epithelial tumors of low malignant potential in contrast to ovarian carcinomas. Hum Pathol 1997, 28(4):443-449. 10.1016/S0046-8177(97)90033-2, 9104944.
30. Maubant S, Cruet-Hennequart S, Dutoit S, Denoux Y, Crouet H, Henry-Amar M, Gauduchon P. Expression of alpha V-associated integrin beta subunits in epithelial ovarian cancer and its relation to prognosis in patients treated with platinum-based regimens. J Mol Histol 2005, 36(1-2):119-129. 10.1007/s10735-004-4273-0, 15704006.
31. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P. Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996, 62(2):260-267. 10.1006/gyno.1996.0225, 8751559.
32. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994, 124(4):619-626. 10.1083/jcb.124.4.619, 2119917, 8106557.
33. Meredith JE, Fazeli B, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell 1993, 4(9):953-961. 275725, 8257797.
34. Maubant S, Cruet-Hennequart S, Poulain L, Carreiras F, Sichel F, Luis J, Staedel C, Gauduchon P. Altered adhesion properties and alphav integrin expression in a cisplatin-resistant human ovarian carcinoma cell line. Int J Cancer 2002, 97(2):186-194. 10.1002/ijc.1600, 11774263.
35. Vellon L, Menendez JA, Liu H, Lupu R. Up-regulation of alphavbeta3 integrin expression is a novel molecular response to chemotherapy-induced cell damage in a heregulin-dependent manner. Differentiation 2007, 75(9):819-830. 10.1111/j.1432-0436.2007.00241.x, 17999741.